Saudi ArabiaTuberculosis profile
Population  2017 33 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1 (0.93–1.2) 3.2 (2.8–3.5)
Mortality (HIV+TB only) 0.02 (0.014–0.026) 0.06 (0.04–0.08)
Incidence  (includes HIV+TB) 3.3 (2.8–3.8) 10 (8.6–12)
Incidence (HIV+TB only) 0.12 (0.1–0.14) 0.37 (0.31–0.44)
Incidence (MDR/RR-TB)** 0.12 (0.089–0.15) 0.36 (0.27–0.46)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.16 (0.16–0.17) 0.85 (0.79–0.92) 1 (0.93–1.1)
Males 0.18 (0.17–0.18) 2.1 (1.9–2.4) 2.3 (2–2.6)
Total 0.34 (0.32–0.35) 3 (2.5–3.4) 3.3 (2.8–3.8)
TB case notifications, 2017  
Total cases notified 2 925
Total new and relapse 2 865
          - % tested with rapid diagnostics at time of diagnosis 40%
          - % with known HIV status 76%
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.33 (0.27–0.39)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 83 4%
          - on antiretroviral therapy 83 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  84
(70–98)
Estimated % of TB cases with MDR/RR-TB 2.6% (2–3.2) 20% (16–25)  
% notified tested for rifampicin resistance 46% 53% 1 360
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 47, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 15, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 75% 2 885
Previously treated cases, excluding relapse, registered in 2016 53% 85
HIV-positive TB cases registered in 2016 51% 45
MDR/RR-TB cases started on second-line treatment in 2015 38% 45
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 2%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
32% (24–50)
TB financing, 2018  
National TB budget (US$ millions) 20
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-09-24 Data: www.who.int/tb/data